Page 17 - PharmBio2122_25June21
P. 17

                                                                                                                                                                                                                                          SINGAPORE PHARMBIO GUIDE 2021/2022
   from the SIRI assessment is Amgen. At ITAP this year, Amgen shared about their experience of using the SIRI assessment toidentifyareasthathelpedthemfurther optimise their manufacturing operations through the use of process analytic technology (“PAT”).
In 2017, the Pharma Innovation Programme Singapore (“PIPS”) – a partnership between GSK, MSD and Pfizerwaslaunched.Theconsortium has been working on more than 10 different projects to transform small molecule manufacturing operations and technologies for greater efficiencies. Some of the areas being explored under PIPS include bio-catalysis, continuous manufacturing, advanced process control, digitalisation, and enhanced pharmaceutical operations. Due to the success of PIPS, there are plans to expand this initiative to other modalities such as biologics manufacturing.
GROWING STARTUP ECOSYSTEM
To develop a globally competitive and innovative biomedical sector, Singapore is also building on the base of Big Pharma companies to grow the biotech community through financing and commercialisation interventions. Through these interventions, Singapore aims to foster greater collaborations across public and private stakeholders and drive more innovative drug development outcomes.
As of 2019, there are more than 350 biotechnology and medical technology companies in Singapore. This pool of Singapore-based companies continues to grow and mature across various therapeutic areas such as oncology and infectious diseases. For example, in 2018, MediSix Therapeutics, a Singapore-based immune engineering biotechnology firm, successfully raised US$20 million in Series A funding as led by Lightstone Ventures, TemasekHoldingsandOsageUniversity Partners. Founded by Professor Dario Campana, a known leader in the field of cancer therapies and immunotherapies, MediSix has since used the financing to build its team in Singapore, advance product development, and initiate pre- clinical studies. In the same year, Veredus Laboratory, a Singaporean molecular diagnostics kit maker, was acquired by Japanese diagnostics company, Sekisui Medical, for an estimated US$83 million.
To support Singapore-based biotechs in their commercialisation efforts, the Singapore government set up the National Research Fund (“NRF”)-Temasek IP commercialisation vehicle in 2018. The vehicle co-invests in start-ups, whose business models are underpinned by IP generated from publicly-funded research. NRF and Temasek have each committed S$50 million to co-invest in Singapore- based early-stage high-tech companies, including biotech start-ups. The Diagnostics Development Hub (“DxD Hub”)
by A*ccelerate (commercialisation arm of the Agency for Science, Technology and Research (“A*STAR”)) also helps organisations to accelerate the transformation of IPs into clinically- validated diagnostic devices by bringing together expertise from different stakeholders. To date, the DxD Hub has successfully formed collaborations between healthcare communities, like SingHealth and the National Healthcare Group, and academic research organisations, like the Singapore Clinical Research Institute. For example, MiRXES, a Singapore-based biotechnology firm spun-off from A*STAR, has worked closely with partners within the DxD Hub to develop and commercialise an early blood-based diagnostic platform that detects various cancers, including breast and gastric cancer. These partners include the Singapore Gastric Cancer Consortium that has helped MiRXES to deliver their lab research to clinicians and doctors.
EXPANDING NEW MODALITIES
Cell and Gene Therapy (“C>”), a growing modality that promises curative treatments,continuestogainprominence after recent FDA approvals of CAR T-cell therapies – Kymriah and Yescarta, and gene therapies – Luxturna and Zolgensma. To ensure that Singapore is able to capitalise on opportunities from C>, the government has invested SS$80 million to establish three manufacturing technology
 11
























































































   15   16   17   18   19